Cancer News and Research

Latest Cancer News and Research

Phase Forward's DefineValidator tool available for CDISC adopters

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced the release of its DefineValidator tool, Release 1.0, as a free download for CDISC adopters.

20 Oct 2009

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

Celgene Corporation announced that updated results of a phase II, multi-center, randomized, double-blind, placebo-controlled, three-arm study of apremilast in adult patients with psoriatic arthritis (CC-10004-PSA-001) were presented today at the American College of Rheumatology (ACR) 2009 annual meeting in Philadelphia, PA.

20 Oct 2009

UT student receives fellowship grant for pre-eclampsia research

Roxanna Irani, a M.D./Ph.D. student at The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS), has received a $10,000 fellowship for her efforts to better understand a condition known as pre-eclampsia that threatens the lives of expectant women and their unborn children.

20 Oct 2009

Health Canada issues Notice of Non-Compliance to Winston Laboratories for CIVANEX

Winston Laboratories, Inc. (“Winston Labs”), a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. today announced that it has received a Notice of Non-compliance (“NON”) from the Therapeutics Drug Directorate, Health Canada (the “Directorate”) for its New Drug Submission (NDS) for CIVANEX (zucapsaicin cream 0.075%) for the treatment of the signs and symptoms of osteoarthritis.

20 Oct 2009

Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma

Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biotherapeutics company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced that the European Medicines Agency (EMEA) has granted Orphan Drug Designation to Jennerex's product JX-594 for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. JX-594 is expected to enter a Phase 3 pivotal trial in the second half of 2010.

20 Oct 2009

FDA approves new oral medication for renal cell carcinoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.

20 Oct 2009

Interim results from Phase 1 CAL-101 trial for chronic lymphocytic leukemia

Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase (PI3K) inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of interim results from the ongoing Phase 1 trial evaluating CAL-101, an oral delta-selective PI3K inhibitor, demonstrating promising clinical responses in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

20 Oct 2009

Antioxidant extracts of G.biloba leaves may protect cells from radiation damage

Antioxidant extracts of the leaves of the Gingko biloba tree may protect cells from radiation damage, according to a study published in the International Journal of Low Radiation. The discovery may one day be used to help reduce side effects in cancer patients undergoing radiotherapy.

20 Oct 2009

Article evaluating StemEx therapy for leukemia and lymphoma to be published

Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma.

19 Oct 2009

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.

19 Oct 2009

Walgreens, aVinci Media launch initiative for breast cancer awareness, raises more than $50,000

Walgreens and aVinci® Media have launched a very successful national initiative to raise vital funds and awareness for breast cancer research and support. On Oct. 7, Walgreens offered aVinci's My Personal Movie slideshow DVDs, which normally retail for $19.99, for only $1.

19 Oct 2009

Website answers questions about 'end of life'

Questions about end of life are as old as humanity, yet they can be new and overwhelming when someone we care about is dying.

19 Oct 2009

Federal grant for ecstasy research

A so-called "club drug" - typically not used all that often by those who take it - can still have the potential to cause a lot of damage among some users, say University of Cincinnati researchers. Trials are underway to trace the effects of ecstasy and to see who's most at risk. The study is supported by $471,000 in federal stimulus funds awarded by the National Institutes of Health and spread out over two years.

19 Oct 2009

24 Hour Data to support breast cancer awareness, to donate 5% of its October sales to NBCF

24 Hour Data today announced its support for Breast Cancer Awareness Month. In an effort to raise awareness about the importance of early detection of breast cancer, the Dallas-based company will donate 5% of its October sales to the National Breast Cancer Foundation, Inc. (NBCF).

19 Oct 2009

Study on the economic impact of antibiotic overuse and antibiotic-resistant infections

The Alliance for the Prudent Use of Antibiotics (APUA) and Cook County Hospital (currently John H. Stroger, Jr. Hospital of Cook County), today announced the release of an eye-opening study on the economic impact of antibiotic overuse and antibiotic-resistant infections (ARIs) sponsored by an unrestricted educational grant from bioMerieux and the Centers for Disease Control and Prevention (CDC).

19 Oct 2009

Alnara Pharmaceuticals’ announces results of its international Phase 3 study of liprotamase

Alnara Pharmaceuticals, a pharmaceutical company developing novel, non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, today announced results from an international, Phase 3 open-label, long-term safety study demonstrating the safety and nutritional benefits of liprotamase, a novel pancreatic enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF).

19 Oct 2009

Cancer News and Research

Latest Cancer News and Research

Phase Forward's DefineValidator tool available for CDISC adopters

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

UT student receives fellowship grant for pre-eclampsia research

Health Canada issues Notice of Non-Compliance to Winston Laboratories for CIVANEX

Jennerex' JX-594 granted European Orphan Drug Designation for the treatment of hepatocellular carcinoma

FDA approves new oral medication for renal cell carcinoma

Interim results from Phase 1 CAL-101 trial for chronic lymphocytic leukemia

Antioxidant extracts of G.biloba leaves may protect cells from radiation damage

Article evaluating StemEx therapy for leukemia and lymphoma to be published

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

Walgreens, aVinci Media launch initiative for breast cancer awareness, raises more than $50,000

Website answers questions about 'end of life'

Federal grant for ecstasy research

24 Hour Data to support breast cancer awareness, to donate 5% of its October sales to NBCF

Study on the economic impact of antibiotic overuse and antibiotic-resistant infections

Alnara Pharmaceuticals’ announces results of its international Phase 3 study of liprotamase

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

Philippines and Malaysian regulatory agencies approve Celsion’s Phase III Thermodox trial

Scientists explore what is behind the feeling of not being competent

Durham VA Medical Center receives Daxor's BVA-100 Blood Volume Analyzer

Understanding the DNA Damage Response in Innate Immunity eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in